bioMérieux invests in personalised cancer tests with $60m AviaraDx deal
This article was originally published in Clinica
Executive Summary
Consistent with its strategy to capitalise on the cancer and personalised medicine markets, French in vitro diagnostics company bioMérieux acquired AviaraDx, a firm specialising in molecular diagnostic tests for cancers.